Compare MGM Resorts International (MGM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs ResMed Inc. — how do they compare? MGM Resorts International trades at $29.27 (market cap $7.55B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 4.2× MGM Resorts International's market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and ResMed Inc. for 51 Days on average.
| MGM | RMD | |
|---|---|---|
Market Cap | $7.55B | $31.89B |
Volume | 5,342,346 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $275.96 |
52-Week Low | $29.27 | $182.82 |
Typical Hold Time | 91 Days | 51 Days |
Enterprise Value | $34.85B | $31.24B |
Dividend Yield | 0.03% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $30.01, showing minimal daily movement. The stock is in a bearish technical trend with recent pressure following the collapse of a proposed acquisition by Barry Diller's People Inc. Fundamentally, revenue remains stable near $17.5 billion, but net income margin has compressed to 2.4% in 2025. The company maintains strong operating cash flow of $2.53 billion, though net cash flow was negative $338 million. Analyst sentiment is mixed but leans positive, with a consensus price target of $48.75 implying significant upside.
The investment outlook for MGM hinges on its ability to stabilize profitability and navigate deal uncertainty. The primary opportunity lies in the substantial discount to analyst targets, while risks include execution on potential acquisitions, competitive pressures in the gaming sector, and macroeconomic sensitivity. The stock's current valuation multiples, such as a P/E of 18.19, appear reasonable if earnings can recover.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
